Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild Dementia Clear all
Completed Phase 2 Interventional Results available

Resveratrol for Alzheimer's Disease

NCT01504854
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Resveratrol, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease

NCT01636596
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Insulin LISPRO
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
50 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

NCT04124029
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
Interventions
No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Device · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

NCT01716637
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Etanercept, Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Biological · Dietary Supplement
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
60 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Coral Springs, Florida • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)

NCT02414282
View directory record Official record
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

Living Alone in Old Age With Cognitive Impairment

NCT03330587
View directory record Official record
Conditions
Living Alone, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

NCT01028053
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Flutemetamol (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Memory Functions in Mild Alzheimer's Disease

NCT04785053
View directory record Official record
Conditions
Alzheimer Disease
Interventions
transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Home-Based Assessment for Alzheimer Disease Prevention

NCT00546767
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Mail and Live Phone, Interactive Voice Response (IVR), Home-based Computer Kiosk, Traditional Evaluation Instruments
Behavioral
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
75 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

NCT07553338
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
Interventions
Leronlimab (700mg)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

NCT05189106
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Baricitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment

NCT04073628
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care

NCT01993836
View directory record Official record
Conditions
Alzheimers Disease, Postoperative Delirium, Post Operative Cognitive Dysfunction
Interventions
Total intravenous anesthesia with propofol, General anesthesia with isoflurane
Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

NCT07127133
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Dementia
Interventions
Insole and ankle device
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
55 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

NCT02791191
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3202626, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Irvine, California • Sacramento, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PET Changes in Alzheimer's Disease (AD)

NCT00094913
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
20 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners

NCT05187117
View directory record Official record
Conditions
Dementia, Mild, Mild Cognitive Impairment, Disability Physical, Impairment, Cognitive, Caregiver Burden, Quality of Life, Depression
Interventions
CAPABLE Family - Open Label Pilot, CAPABLE Family - Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

NCT00329706
View directory record Official record
Conditions
Dementia
Interventions
FDG-PET brain scan
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

NCT04784416
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 17, 2026, 5:15 AM EDT